CSBio CSBio

X
[{"orgOrder":0,"company":"Tabuk Pharmaceuticals","sponsor":"Biocon","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocon Ltd Partners with Tabuk Pharmaceuticals to Commercialise Its Speciality Generic Medicines in the Middle East","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"SAUDI ARABIA","productType":"Peptide","productStatus":"Biosimilar","date":"December 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Tabuk Pharmaceuticals"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the terms of this agreement, Tabuk Pharmaceuticals will hold the marketing authorisation for select speciality products including Glaricon and be responsible to register, importing, and promoting them in Saudi Arabia and other Middle East countries.

            Lead Product(s): Insulin Glargine

            Therapeutic Area: Endocrinology Product Name: Glaricon

            Highest Development Status: Approved Product Type: Peptide

            Partner/Sponsor/Collaborator: Biocon

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement December 07, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY